Case Study: a pharmaceutical company restores Phase 3 colorectal enrollment with Precision for Medicine Central Lab Services

Pharmaceutical restores Phase 3 colorectal enrollment with Precision for Medicine across 90+ sites

The customer, a Sweden-based pharmaceutical company, was facing stalled enrollment in its first North American Phase 3 colorectal cancer trial. Precision for Medicine was engaged to provide site management and clinical monitoring support to help navigate this new operational landscape.

Precision for Medicine built a centralized prescreening tracker, which identified a hemoglobin eligibility threshold that was systematically excluding eligible patients. They presented this data to the sponsor, leading to a protocol amendment. Following this change, enrollment recovered and the study successfully met its target of over 490 patients across more than 90 sites, demonstrating how operational intelligence can reshape a trial's trajectory.

Pharmaceutical